Monday, February 16, 2026
28 C
Bengaluru

Specially Designed Case Study based Modules for Pharma Marketing Professionals

DEPA 2.0 Workshop – Open to participants from all companies – Starting February 5th, 2022.

We can also conduct a customized workshop to address your company’s specific needs on dates and timelines convenient to you.

The 4- Module Workshop series will be moderated by Anup Soans with international and Indian faculty – Dr. Peter Velev, a medical doctor and pharma industry veteran, and Salil Kallianpur, pharma marketing veteran and digital brand coach.

Objective: More than digitalizing your product promotions, the case calls for building and engaging your brand community through digital solutions that create memorable customer experiences.

With the new normal emerging, the traditional Pharma commercial model needs to be relooked by exploring alternative channels of engagement, which offer opportunities to create value for customers.

Company-specific digital adoption workshops to experience how a brand can be promoted using the omnichannel approach with field force involvement.

Interactive Webinars extended with Virtual Event – 4 Modules – 2.0 hours each over 4 weeks.

Register Now – https://medicinman.net/depa20-request-payment-link/register-for-depa-2-0/

https://medicinman.net/depa20-request-payment-link/register-for-depa-2-0/

Hot this week

Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich

When a new cancer drug shows promise, it trends...

From Overuse to Overreaction: Recalibrating India’s C-Section Debate

India’s caesarean section debate is drifting toward polarisation. On one...

Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift

In big pharma, leadership changes are rarely impulsive. They...

THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL

How a niche Indian topicals manufacturer outgrew its CDMO...

Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?

Transparency, Trust, and the Problem of “Invisible Evidence” in...

Topics

From Overuse to Overreaction: Recalibrating India’s C-Section Debate

India’s caesarean section debate is drifting toward polarisation. On one...

Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift

In big pharma, leadership changes are rarely impulsive. They...

THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL

How a niche Indian topicals manufacturer outgrew its CDMO...

Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?

Transparency, Trust, and the Problem of “Invisible Evidence” in...

The Uncomfortable Truth about Indian Generics: Untangling the Conundrum

India’s pharmaceutical industry occupies a unique and powerful position...

IQVIA vs. PharmaTrac: Indian Pharma Market Data

Here is an analytical blog comparing the IQVIA MFR...
spot_img

Related Articles

spot_imgspot_img